Standout Papers

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma 2005 2026 2012 2019 15.6k
  1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma (2005)
    Roger Stupp, Warren Mason et al. New England Journal of Medicine
  2. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma (2005)
    Monika E. Hegi, Annie‐Claire Diserens et al. New England Journal of Medicine
  3. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2010)
    Patrick Y. Wen, David R. Macdonald et al. Journal of Clinical Oncology
  4. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (2012)
    Annika Malmström, Bjørn Henning Grønberg et al. The Lancet Oncology
  5. Glioma (2015)
    Michael Weller, Wolfgang Wick et al. Nature Reviews Disease Primers
  6. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial (2013)
    Mark R. Gilbert, Meihua Wang et al. Journal of Clinical Oncology
  7. Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity (2008)
    Monika E. Hegi, Lili Liu et al. Journal of Clinical Oncology
  8. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide (2004)
    Monika E. Hegi, Sophie Godard et al. Clinical Cancer Research
  9. Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide (2002)
    Roger Stupp, Pierre-Yves Dietrich et al. Journal of Clinical Oncology
  10. Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma (2008)
    Anastasia Murat, Eugenia Migliavacca et al. Journal of Clinical Oncology
  11. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2009)
    Michael Weller, Roger Stupp et al. Nature Reviews Neurology
  12. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma (2014)
    Michael Weller, Martin J. van den Bent et al. The Lancet Oncology
  13. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014)
    Roger Stupp, M. Brada et al. Annals of Oncology
  14. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018)
    Daniel J. Brat, Kenneth Aldape et al. Acta Neuropathologica
  15. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas (2020)
    Daniel J. Brat, Kenneth Aldape et al. Acta Neuropathologica
  16. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment (2023)
    Víctor A. Arrieta, Crismita Dmello et al. Journal of Clinical Investigation
  17. Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial (2024)
    Alexandre Carpentier, Roger Stupp et al. Nature Communications

Immediate Impact

5 by Nobel laureates 22 from Science/Nature 234 standout
Sub-graph 1 of 17

Citing Papers

Fluorescent Probes for Disease Diagnosis
2024 Standout
Glioblastoma and Other Primary Brain Malignancies in Adults
2023 Standout
82 intermediate papers

Works of Roger Stupp being referenced

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
and 49 more

Author Peers

Author Last Decade Papers Cites
Roger Stupp 30511 13661 9311 15389 373 48.5k
Martin J. van den Bent 34321 14555 7911 12386 573 49.5k
Patrick Y. Wen 23253 11228 9683 12006 775 41.8k
Wolfgang Wick 21694 8574 7352 12684 617 40.8k
Guido Reifenberger 28242 8661 5692 17931 348 46.0k
Alba A. Brandes 23019 9461 6491 9884 356 33.2k
Jill S. Barnholtz‐Sloan 18897 9065 6891 11383 433 39.7k
Andreas von Deimling 30112 10166 8940 22183 645 57.6k
J. Gregory Cairncross 24419 9272 5759 12216 168 35.3k
David N. Louis 29974 15368 13929 23780 318 62.6k
David A. Reardon 20314 7151 8565 10207 552 33.1k

All Works

Loading papers...

Rankless by CCL
2026